We are pleased to announce that the NINDS Clinical Trials Methodology Course (CTMC) is accepting applications for the 2020 cohort. The overarching goal of the CTMC is to help junior investigators develop scientifically rigorous, yet practical clinical trial protocols.
The INC Pilot/Feasibility Core is now accepting applications for Pilot Awards. The goal of the INC Pilot Awards is to support investigators wishing to perform single or multi-site projects that will advance the diagnosis, clinical trial readiness, management, and/or treatment of CMT. Both senior investigators wishing to expand their research into new directions and Junior INC investigators are encouraged to apply.
MGNet, an NIH-funded Rare Diseases Clinical Research Consortium (RDCRC) in partnership with the Myasthenia Gravis Foundation of America and Concur MG, is seeking proposals that address the clinical research field in Myasthenia Gravis.
The slide presentation from the 2019 NeuroNEXT Annual Meeting in Pittsburgh, PA October 28-29 are now available on the NeuroNEXT private website. They can be accessed under Network Materials > Annual Meetings. Thanks to everyone for a successful meeting!
We are very excited to announce the first ever NINDS podcast for trainees!
The 2019 Clinical Trials Methodology Course was held in Iowa City in July. See below for an informational video from the University of Iowa on how the course helps investigators design large scale neurological studies.
The AAN is collaborating with the Medical University of South Carolina (MUSC) to offer The TRANSCENDS (Training in Research for Academic Neurologists to Sustain Careers and Enhance the Numbers of Diverse Scholars) Scholars program. This program is funded by a NINDS R25. The TRANSCENDS program is designed to train promising early-career neurologists to conduct high-quality neurologic research and achieve a successful academic career.
Program Details
NeuroNEXT was well-represented at the 40th Annual Meeting of the Society for Clinical Trials (SCT) this week. The meeting - hosted in New Orleans, LA, May 19-22, 2019 - featured two invited sessions by NeuroNEXT personnel:
NIH is soliciting for Pain Research Centers to join a clinical trial network. NIH has mounted a major effort to improve pain management as a part of its response to the opioid crisis in America. One cornerstone of that effort is an phase 2 clinical trial network to test new, non-addictive pain therapies in well-phenotyped patients. This is part of a public-private partnership with academia, pharmaceutical companies, biotechnology and device companies.
The dataset from the NN102 SPRINT-MS project is now publicly available from the NINDS repository. Researchers interested in accessing this data should complete the NINDS Data Request Form and send it via email to the NINDS Clinical Research Liaison at: CRLiaison@ninds.nih.gov.
Dr. Robert Fox, PI of the NN102 SPRINT-MS study was the 2019 recipient of Cleveland Clinic's Sones Innovation Award for the advances in progressive multiple sclerosis made by the NN102 study. This award recognizes advances in innovation in the service of improved patient care. Congratulations to Dr. Fox and the NN102 SPRINT-MS team!
Applications for the NINDS-funded Clinical Trials Methodology Course (CTMC) 2019 are due February 28, 2019 at midnight. Application forms and additional details are available at http://neurotrials.training. Early applications may be considered for early acceptance.
The NN104 RHAPSODY primary manuscript has been published in the January 2019 print issue of Annals of Neurology. As the abstract notes, this trial was important for three reasons:
NN101 SMA was recently featured in the Cure SMA newsletter, highlighting the recently-published Recruitment & Retention paper.
Dr. Merit Cudkowicz, Principal Investigator of the NeuroNEXT CCC, was interviewed on CBS News' 60 Minutes on a feature about NFL star Tim Green coping with ALS. Her appearance begins at the 6:15 mark, and she discusses Mr. Green's prognosis and treatment.
The slide presentation from the 2018 NeuroNEXT Annual Meeting in Boston, MA October 18-19 are now available on the NeuroNEXT private website. They can be accessed under Network Materials > Annual Meetings. Thanks to everyone for a successful meeting!
The dataset from the NN101 SMA project is now publicly available from the NINDS repository. Researchers interested in accessing this data should complete the NINDS Data Request Form and send it via email to the NINDS Clinical Research Liaison at: CRLiaison@ninds.nih.gov.
NINDS has issued a press release regarding the publication of the NN102 SPRINT-MS study results in the New England Journal of Medicine. The press release quotes NINDS Director Walter J. Kroshetz, MD, saying the NN102 SPRINT-MS findings "provide a glimmer of hope for people with a form of nultiple sclerosis that causes long-term disability but does not have many treatment options."
The results of the NN102 SPRINT-MS have been posted online at the New England Journal of Medicine.
The National Institute of Neurological Disorders and Stroke announced the renewal of the NeuroNEXT Network for an additional five years of funding.